

**University of California, San Francisco**  
**CURRICULUM VITAE**

**Name:** Deepika Sirohi

**Position:** Associate Professor, Pathology

**Address:** Box 0506  
185 Berry Street Bldg B  
University of California, San Francisco  
San Francisco, CA 94158  
Voice: 415-353-1613  
Email: deepika.sirohi@ucsf.edu

**EDUCATION**

1988 - 1993	Armed Forces Medical College, Pune, India	MBBS	
1997 - 2000	Armed Forces Medical College, Pune, India	MD	Pathology
2011 - 2015	University of Texas Health Science Center at San Antonio, Texas	Residency	Anatomic and Clinical Pathology
2015 - 2016	Cedars Sinai Medical Center, Los Angeles, CA	Fellowship	Genitourinary Pathology Fellowship
2016 - 2017	University of California San Francisco, CA	Fellowship	Molecular Genetic Pathology

**LICENSES, CERTIFICATION**

2013	California Medical Board
2017	State of Utah
2022	Arizona Medical Board

**PRINCIPAL POSITIONS HELD**

1993 - 1997	Army Medical Corps, India	Medical Officer	
2000 - 2010	Army Medical Corps, India	Staff Pathologist	
2017 - 2022	University of Utah School of Medicine and ARUP Laboratories	Assistant Professor Pathology	Pathology
2022 - 2023	University of Utah School of Medicine and ARUP Laboratories	Associate Professor Pathology	Pathology

## OTHER POSITIONS HELD CONCURRENTLY

2018 - 2023	ARUP Laboratories	Section Head Solid Tumor FISH Lab	Pathology
2019 - 2023	Huntsman Cancer Institute	Co-Moderator Molecular Oncology Tumor Board	Pathology

## HONORS AND AWARDS

2016	First Place, Oral Presentation Competition, Annual Resident & Fellow Symposium	Los Angeles Society of Pathologists, Los Angeles, CA
2022	Joe Holden Award for Excellence in Anatomic Pathology	University of Utah, Department of Pathology

## CLINICAL ACTIVITIES

### CLINICAL SERVICES

2017 - 2023	Genitourinary Pathology	8 weeks/year
2017 - 2023	Molecular Oncology	28-30 weeks/year

## PROFESSIONAL ACTIVITIES

### MEMBERSHIPS

2013 - present	United States and Canadian Academy of Pathology, Member
2017 - present	Association of Molecular Pathologists
2021 - present	Genitourinary Pathology Society
2023 - present	American Society of Clinical Oncology

### SERVICE TO PROFESSIONAL ORGANIZATIONS

2019 - 2021	United States and Canadian Academy of Pathology	Genitourinary Pathology Abstract Reviewer
2023 - present	Association of Molecular Pathologists	Solid Tumor Program Committee Representative Solid Tumor abstract reviewer

**SERVICE TO PROFESSIONAL PUBLICATIONS**

2018 - present Adhoc referee, Cancer Cytopathology  
 2019 - present Adhoc referee, American Journal of Clinical Pathology  
 2019 - present Adhoc referee, Tumor Biology  
 2020 - present Review Editor in Pathology, Frontiers  
 2020 - present Adhoc referee, PLoS One  
 2020 - present Adhoc referee, Modern Pathology  
 2021 - present Adhoc referee, Cancers  
 2021 - present Adhoc referee, International Journal of Surgical Pathology  
 2022 - present Adhoc referee, Human Pathology

**INVITED PRESENTATIONS - NATIONAL**

2016	United States and Canadian Academy of Pathology	Podium presentation
2018	American Society of Clinical Pathology	Invited Talk
2018	United States and Canadian Academy of Pathology	Podium presentation
2019	American Society of Clinical Pathology	Invited Talk
2021	United States and Canadian Academy of Pathology	Podium presentation
2022	Precision Oncology Summit	Invited Talk
2023	American Society of Clinical Pathology	Invited Talk

**INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS**

2012	South Central Association of Blood Banks	Podium presentation
2017	Los Angeles Society of Pathologists	Podium presentation
2018	Annual Park City Clinical Pathology Update	Invited Talk
2018	Utah Society of Pathologists	Invited Talk
2019	Annual Park City Clinical Pathology Update	Invited Talk
2020	Huntsman Cancer Institute Town Hall	Invited Talk
2022	Annual Park City Clinical Pathology Update	Invited Talk
2023	Annual Park City Clinical Pathology Update	Invited Talks (2)

## UNIVERSITY AND PUBLIC SERVICE

### SERVICE ACTIVITIES SUMMARY

At University of Utah, I have been involved in recruitment of Faculty for Molecular Oncology, Pathology and Urologic Oncology. I have also served on the interview committee for Molecular Genetic Pathology fellowship.

### DEPARTMENTAL SERVICE

2019 - 2023	University of Utah, Department of Pathology	Molecular Oncology Faculty search committee, representative
2019 - 2023	University of Utah, Department of Pathology	Molecular Genetic Pathology Fellowship Interview committee, representative

## TEACHING AND MENTORING

### TEACHING SUMMARY

My teaching activities have involved didactic lectures and slide sessions for residents and fellows in the field of genitourinary pathology and Molecular Oncology. On job training of residents and fellows in conducted during daily clinical sign outs in these areas. I have also been involved with Labs for Medical Students and continuing education for lab technicians in Molecular Oncology.

### FORMAL TEACHING

Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
2017 - 2022	Molecular Testing of Genitourinary Tumors		Medicine	10
2017 - 2022	Slide session Kidney Tumors		Medicine	16
2017 - 2022	Slide session Genitourinary Tumors		Medicine	16
2018 - 2019	Board Review Genitourinary Tumors		Medicine	16

### INFORMAL TEACHING

2017 - 2023	Genitourinary case review (8 weeks/year with 2 to 3 residents/fellows at the microscope)
2017 - 2023	Molecular Oncology case review (weekly with 2 to 4 residents/fellows)

**MENTORING SUMMARY**

I have mentored residents and fellows in pathology, post doc fellows and R&D scientists in translational research projects with successful publication of the work. The mentoring has involved engaging with the mentees in designing research projects, providing mentoring support in conducting these studies and informative discussions and guidance in preparing manuscripts.

**POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED**

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2020 - 2022	Valarie McMurtry		Research/Scholarly Mentor	Mentor	
2022 - 2022	Nishita Tripathi		Research/Scholarly Mentor	Mentor	
2018 - 2020	Evan Raps		Research/Scholarly Mentor	Mentor	
2020 - 2022	Diane Wilcock		Research/Scholarly Mentor	Mentor	

**RESEARCH AND CREATIVE ACTIVITIES****RESEARCH AND CREATIVE ACTIVITIES SUMMARY**

My research has focused on translational studies involving genitourinary tumors and clinical applications of molecular testing for solid tumors. The projects have encompassed correlation of histomorphological features with underlying molecular findings, understanding the molecular biology of genitourinary tumors and improving the workflow and clinical practices in the field of molecular oncology. My research interest has also included collaborations with basic research scientists studying genitourinary tumors for biomarker discovery.

**RESEARCH AWARDS - CURRENT**

1. 1R21CA277381	Co-Investigator		Knudsen (PI)
NIH/NCI		02/2023	01/2025
Pathomics biomarkers for stratification of clear cell kidney cancers			\$ 423,065 total
Develop quantitative criteria to identify patients who need additional drug treatment after surgery for kidney cancer. This treatment is expected to delay or avoid disease recurrence; however, because of its toxic side effects only patients who are at high risk of cancer recurrence should be treated. Here we propose to develop better criteria for selecting the right patients for treatment after kidney cancer surgery.			
Evaluating histomorphologic features and correlation with annotations for computational AI based digital image analysis			
2. R01 CA217905-01	Collaborator		Koh (PI)
NIH/NCI		09/2017	08/2023

A novel approach for the selective inhibition of HIF-2a in kidney cancer

\$ 348,203 total

This project investigates the strategy of targeting HIF-2a by interfering with tumor-specific iron metabolism. The goals of the project will be to identify the mechanisms by which ISCA2, HIF-2 $\alpha$  and the deregulation of iron metabolism contribute to CRCC progression; and to determine whether this approach of targeting iron metabolism will yield increased therapeutic benefit for patients with CCRCC.

Tissue identification for TMA construction, validating immunohistochemical antibodies and testing and interpreting of the samples

### RESEARCH AWARDS - SUBMITTED

1. R01 CA286161-01	Collaborator		Koh (PI)
NIH/NCI		09/2023	08/2028
Targeting iron-sulfur cluster assembly - a novel vulnerability in kidney cancer			\$ 663,631 total

This project investigates the hypothesis is that “mitochondrial loss/dysfunction during VHL loss in ccRCC that promotes a shift in ISCA2 localization from the mitochondria to the cytosol where it contributes to the cytosolic iron sulfur cluster assembly, which drives ccRCC progression”. The overall goals of the study are to better understand the mechanisms of Fe-S assembly during pVHL loss for the identification of new therapeutic strategies.

Tissue identification for TMA construction, validating research antibodies, testing and interpreting immunohistochemical stains

### RESEARCH AWARDS - PAST

1.	Principal Investigator		
	Department of Pathology, University of California, San Francisco	01/2016	12/2017
	Clinicopathologic and molecular study of Polyoma virus-associated carcinomas of the urologic tract.		\$ 12,000.00 total
	The study investigates the molecular alterations in Polyoma BK virus associated urothelial carcinomas occurring in immunosuppressed individuals post transplant.		
	Study design and conceptualization, data interpretation and analysis.		

2.	Principal Investigator		
	William L. Roberts Fund, ARUP Laboratories and Sarcoma Center Pilot Project Award	10/2018	06/2021
	Clinical Validation of Nanostring nCounter Fusion Panel for Carcinomas		\$ 17,244.00 total
	The study involved experiments to evaluate the clinical efficacy of the Nanostring nCounter Fusion panel for clinical use.		
	Study design and conceptualization, data interpretation and analysis.		

3.	Principal Investigator		
	William L. Roberts Fund, ARUP Laboratories	10/2020	07/2022

	Referral laboratory experience of morphological features and biomarker evaluation of Fumarate Hydratase (FH) deficient neoplasms.		\$ 9,800.00 total
	This project involved identification and characterization of FH deficient neoplasms and molecular analysis for better understanding and morphological characterization.		
	Study design and conceptualization, data interpretation and analysis.		
4.	Principal Investigator		
	GU Cancer Center Pilot Project Award.	12/2019	12/2022
	Comparison of Metabolic and Immuno-Oncologic Pathway Alterations between Responders and Non-Responders to Immunotherapy in Metastatic Clear Cell Renal Cell Carcinomas.		\$ 37,680.00 total
	This project involves transcriptomic analysis of clinically identified responders and non-responders to immunotherapy in patients with clear cell renal cell carcinoma for differences in transcriptomic profile.		
	Study design and conceptualization, data interpretation and analysis.		
5.	Principal Investigator		
	William L. Roberts Fund, ARUP Laboratories	02/2020	12/2022
	Molecular Evaluation of BK Viral DNA Integration in Urothelial Carcinomas from Immunosuppressed Individuals.		\$ 7,419.00 total
	This project investigates transcriptomic profile of Polyoma BK virus associated urothelial carcinoma for pathway alterations and viral integration.		
	Study design and conceptualization, data interpretation and analysis.		
6.	Co-Investigator		Connors (PI)
	William L. Roberts Fund, ARUP Laboratories	10/2020	12/2022
	ctDNA Control Harmonization Collaboration with FNIH		
	This project evaluates the variability across laboratories in ctDNA testing.		
	Lead role at ARUP Laboratories in performing ctDNA tests.		
7.	Co-Investigator		Tasdizen (PI)
	Computational Oncology Research Initiative Grant	07/2020	12/2021
	A Computational Pathology Infrastructure for Clinical Outcomes Studies at HCI.		\$ 30,000.00 total
	This project develops a model for creating research database infrastructure that incorporates digital pathology image base.		
	Advisor on pathology image database and integration into research database.		
8.	190701 Collaborator		Koh (PI)
	HCI ET CCSG Pilot Grant	07/2018	03/2019
	Characterization of key drivers of tumor progression in kidney cancer		\$ 75,000 total

We will perform single cell mRNA sequencing to identify and characterize HIF-1 $\alpha$  positive cells within CCRCC primary patient tumors, and delineate their role in CCRCC progression. We will also generate and sequence patient derived xenografts (PDXs) derived from these tumors, using engraftment ability as a surrogate for metastatic potential, to identify key drivers of metastasis.

Validating and interpreting immunohistochemical antibodies for the project

9.	Collaborator		Koh (PI)
	Genitourinary Cancer Center Pilot Project Award	06/2019	05/2020
	Investigation of the HIF-iron Axis as Predictors of Response in Metastatic Kidney Cancer		\$ 46,250 total
	This project will be performed with co-investigators Dr. Neeraj Agarwal and Dr. Benjamin Maughan from HCI to investigate the role of HIFs and iron as biomarkers for treatment response in kidney cancer.		
	Validating and interpreting immunohistochemical antibodies. Testing iron content of tumor samples.		

10.	Collaborator		Koh (PI)
	HCI GU Cancer Center Pilot Project	07/2021	06/2022
	Investigating the role of neurofibromin in driving treatment response in kidney cancer		\$ 50,000 total
	This study will investigate the potential role of neurofibromin in promoting resistance to anti-angiogenic therapy in kidney cancer by building and utilizing tumor microarrays from archival kidney cancer samples available from the HCI Biorepository.		
	Tissue identification for constructing TMAs, validating and interpreting immunohistochemical antibodies.		

11.	Collaborator		Koh (PI)
	HCI ET Pilot Project Award	01/2021	06/2022
	Neurofibromin Stabilization as a Therapeutic Strategy in Kidney Cancer		\$ 30,000 total
	This project is linked to the GU Pilot grant and involves performing a high-throughput screen to identify small molecules to stabilize neurofibromin in kidney cancer cells.		
	Tissue identification for constructing TMAs, validating and interpreting immunohistochemical antibodies.		

## PEER REVIEWED PUBLICATIONS

1. Repetto F, Sirohi D, Greipp P, Mahlow J. Incidental Detection of TFEB-Amplified Renal Cell Carcinoma by Colocated Gene Amplification of CCND3 (6p21): A Case Report and Review of the Literature. *Int J Surg Pathol*. 2023 Jul 2. Online ahead of print.
2. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. *Oncologist*. 2023 Mar 23. Online ahead of print.
3. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson



- DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi D. Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. *Arch Pathol Lab Med*. 2023 Mar 15. Online ahead of print.
4. Schwartz CJ, Ruiz J, Bean GR, Sirohi D, Joseph NM, Hosfield EM, Jacobs TW, Mukhtar RA, Chen YY, Krings G. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. *Mod Pathol*. 2023 Feb 6;36(5):100125. Online ahead of print.
  5. Zhang W, Koh MY, Sirohi D, Ying J, Brintz BJ, Knudsen BS. Predicting IHC staining classes of NF1 using features in the hematoxylin channel. *J Pathol Inform*. 2023 Jan 25;14:100196.
  6. McMurtry V, Mahlow J, Coleman JF, Deftereos G, Jattani R, Bastien RRL, Durtschi J, Jarboe E, Lomo L, Sirohi D. Morphologic Characteristics and Mutational Analysis of Fumarate Hydratase Deficient Kidney and Smooth Muscle Tumors. *Am J Clin Pathol*. 2023 Feb 1;159(2):164-171.
  7. McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U. Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. *Biomedicines*. 2022 Dec 7;10(12):3170.
  8. Winter JM, Fresenius HL, Cunningham CN, Wei P, Keys HR, Berg J, Bott A, Yadav T, Ryan J, Sirohi D, Tripp SR, Barta P, Agarwal N, Letai A, Sabatini DM, Wohlever ML, Rutter J. Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. *Elife*. 2022 Nov 21;11:e82860.
  9. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. *Mol Cancer Ther*. 2022 Dec 2;21(12):1857-1861.
  10. Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. *Oncogene*. 2022 Oct;41(42):4709-4723.
  11. Mahlow J, Sanchez A, Barry M, Sirohi D. Composite pheochromocytoma/paraganglioma-ganglioneuroma with a germline SDHC mutation: a first of its kind case report. *Histopathology*. 2022 Nov;81(5):682-685.
  12. Mohanty SK, Lobo A, Williamson SR, Shah RB, Trpkov K, Varma M, Sirohi D, Aron M, Kandukari SR, Balzer BL, Luthringer DL, Ro J, Osunkoya AO, Desai S, Menon S, Nigam LK, Sardana R, Roy P, Kaushal S, Midha D, Swain M, Ambekar A, Mitra S, Rao V, Soni S, Jain K, Diwaker P, Pattnaik N, Sharma S, Chakrabarti I, Sable M, Jain E, Jain D, Samra S, Vankalakunti M, Mohanty S, Parwani AV, Sancheti S, Kumari N, Jha S, Dixit M, Malik V, Arora S, Munjal G, Gopalan A, Magi-Galluzzi C, Dhillon J. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. *Int J Surg Pathol*. 2022 Aug 9:10668969221116629. Online ahead of print.
  13. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous

- differentiation compared to pure urothelial carcinoma. *Urol Oncol*. 2022 Nov;40(11):493.e1-493.e7.
14. Wilcock DM, Sirohi D, Coleman JF, Gulbahce HE. Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity. *Hum Pathol*. 2022 Aug;126:129-135.
  15. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi D. Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. *Int J Surg Pathol*. 2022 Oct;30(7):734-742.
  16. Smith SC, Hamza A, Sirohi D, Amin MB. Response to the Letter to the Editor Entitled "Do We Have Sufficient Evidence to Define Prognosis for 'Low-grade' Fumarate Hydratase-deficient Renal Cell Carcinoma?". *Adv Anat Pathol*. 2022 May 1;29(3):181-182.
  17. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B. Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. *Clin Genitourin Cancer*. 2022 Jun;20(3):e233-e243.
  18. Jedrzkiewicz J, Sirohi D, Uvezovic N, Gulbahce HE. RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. *Mod Pathol*. 2022 Apr;35(4):549-553.
  19. Wilcock DM, Schmidt RL, Furtado LV, Matynia AP, Deftereos G, Sirohi D. Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization. *Appl Immunohistochem Mol Morphol*. 2022 Jan 1;30(1):19-26.
  20. Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzeig R, Kohli M, Pal SK, Agarwal N. Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. *Cancers (Basel)*. 2021 Sep 30;13(19):4951.
  21. Hamza A, Sirohi D, Smith SC, Amin MB. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors. *Adv Anat Pathol*. 2021 Nov 1;28(6):396-407.
  22. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzeig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. *Oncologist*. 2021 Dec;26(12):1006-e2129.
  23. Lin E, Hahn AW, Nussenzeig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. *Oncologist*. 2021 Sep;26(9):751-760.
  24. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho

- TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1 $\alpha$  Is an Independent Prognostic Indicator in Kidney Cancer. *Clin Cancer Res.* 2021 Jun 1;27(11):3265.
25. Swami U, Haaland B, Kessel A, Nussenzevig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. *J Urol.* 2021 Mar;205(3):709-717.
26. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1 $\alpha$  Is an Independent Prognostic Indicator in Kidney Cancer. *Clin Cancer Res.* 2020 Sep 15;26(18):4970-4982.
27. Gandhi JS, Smith SC, Paner GP, McKenney JK, Sekhri R, Osunkoya AO, Baras AS, DeMarzo AM, Cheville JC, Jimenez RE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Sirohi D, Kaushal S, Sangoi A, Robinson BD, Kweldam CF, Humphrey PA, Hansel DE, Schultz L, Magi-Galluzzi C, Przybycin CG, Shah RB, Mehra R, Kunju LP, Aron M, Kryvenko ON, Kench JG, Kuroda N, Tavora F, van der Kwast T, Grignon DJ, Epstein JI, Reuter VE, Amin MB. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists. *Am J Surg Pathol.* 2020 May;44(5):673-680.
28. Sirohi D, Schmidt RL, Aisner DL, Behdad A, Betz BL, Brown N, Coleman JF, Corless CL, Deftereos G, Ewalt MD, Fernandes H, Hsiao SJ, Mansukhani MM, Murray SS, Niu N, Ritterhouse LL, Suarez CJ, Tafe LJ, Thorson JA, Segal JP, Furtado LV. Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. *J Mol Diagn.* 2020 Feb;22(2):284-293.
29. Gulbahce HE, Coleman JF, Sirohi D. Interference of Tissue-Marking Dyes With Fluorescence In Situ Hybridization Assays. *Arch Pathol Lab Med.* 2019 Nov;143(11):1299.
30. Sirohi D, Gandhi J, Amin MB, Luthringer DJ. Amyloidosis of the bladder and association with urothelial carcinoma: report of 29 cases. *Hum Pathol.* 2019 Nov;93:48-53.
31. Sirohi D, Devine P, Grenert JP, van Ziffle J, Simko JP, Stohr BA. TP53 structural variants in metastatic prostatic carcinoma. *PLoS One.* 2019 Jun 19;14(6):e0218618.
32. Lin L, Sirohi D, Coleman JF, Gulbahce HE. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing Guidelines Results From a National Reference Laboratory. *Am J Clin Pathol.* 2019 Sep 9;152(4):479-485.
33. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. *Mod Pathol.* 2018 Sep;31(9):1429-1441.
34. Li P, You S, Nguyen C, Wang Y, Kim J, Sirohi D, Ziembiec A, Luthringer D, Lin SC, Daskivich T, Wu J, Freeman MR, Saouaf R, Li D, Kim HL. Genes involved in prostate cancer progression determine MRI visibility. *Theranostics.* 2018 Feb 12;8(7):1752-1765.

35. Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Comp erat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. *Am J Surg Pathol*. 2018 Mar;42(3):279-292.
36. Sirohi D, Garg K, Simko JP, Grenert JP. Renal NUT carcinoma: a case report. *Histopathology*. 2018 Feb;72(3):528-530.
37. Patel DN, Nguyen C, Sirohi D, Falahatian V, Saouaf R, Luthringer D, Li D, Kim HL. Use of cylindrical coordinates to localize prostate cancers on MRI and prostatectomy pathology. *Urol Oncol*. 2017 Dec;35(12):673.e15-673.e20.
38. Chan E, Bollen AW, Sirohi D, Van Ziffle J, Grenert JP, Kline CN, Tihan T, Perry A, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. *Acta Neuropathol*. 2017 Oct;134(4):671-673.
39. Murkey JA, Chew KW, Carlson M, Shannon CL, Sirohi D, Sample HA, Wilson MR, Vespa P, Humphries RM, Miller S, Klausner JD, Chiu CY. Hepatitis E Virus-Associated Meningoencephalitis in a Lung Transplant Recipient Diagnosed by Clinical Metagenomic Sequencing. *Open Forum Infect Dis*. 2017 Jun 13;4(3):ofx121.
40. Sirohi D, Smith SC, Ohe C, Colombo P, Divatia M, Dragoescu E, Rao P, Hirsch MS, Chen YB, Mehra R, Amin MB. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. *Hum Pathol*. 2017 Sep;67:134-145.
41. Sirohi D, Smith SC, Epstein JI, Balzer BL, Simko JP, Balitzer D, Benhamida J, Kryvenko ON, Gupta NS, Paluru S, da Cunha IW, Leal DN, Williamson SR, de Peralta-Venturina M, Amin MB. Pericytic tumors of the kidney-a clinicopathologic analysis of 17 cases. *Hum Pathol*. 2017 Jun;64:106-117.
42. Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, Hovelson D, Luthringer DJ, Martignoni G, Chen YB, Tomlins SA, Mehra R, Amin MB. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. *Histopathology*. 2017 Jul;71(1):42-52.
43. Sirohi D, Mamun S, Jagirdar J. Hilar/endobronchial NUT midline carcinoma: A case report. *Hum Pathol (N Y)*,2017:743-6.
44. Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, Cani AK, Hovelson DH, Omata K, McHugh JB, Jochum W, Colecchia M, Amin M, Divatia MK, Hes O, Menon S, Werneck da Cunha I, Tripodi S, Brimo F, Gill AJ, Osunkoya AO, Magi-Galluzzi C, Sibony M, Williamson SR, Nesi G, Picken MM, Maclean F, Agaimy A, Cheng L, Epstein JI, Reuter VE, Tickoo SK, Tomlins SA, Amin MB. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma. *Am J Surg Pathol*. 2016 Nov;40(11):1457-1472.
45. McFaddin C, Sirohi D, Castro-Echeverry E, Fernandez MP. Desmoplastic trichoepithelioma with pseudocarcinomatous hyperplasia: a report of three cases. *J Cutan Pathol*. 2015 Feb;42(2):102-7.

46. Sirohi D, Swimley K, Profit AL, Riddle ND. Her-2 neu negative lipid rich breast carcinoma in an immunocompromised patient. *Hum Pathol (N Y)*, 2015;2(4), 99-102.
47. Sharma R, Sirohi D, Sinha R, Menon PS. Palatal perforation secondary to tuberculosis: a case report. *J Maxillofac Oral Surg*. 2013 Sep;12(3):326-8.
48. Policarpio-Nicolas ML, Sirohi D. Macrofollicular variant of papillary carcinoma, a potential diagnostic pitfall: A report of two cases including a review of literature. *Cytojournal*. 2013 Aug 30;10:16.
49. Brown AF, Sirohi D, Fukuoka J, Cagle PT, Policarpio-Nicolas M, Tacha D, Jagirdar J. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. *Arch Pathol Lab Med*. 2013 Sep;137(9):1274-81.
50. Jagirdar J, Chikkamuniyappa S, Sirohi D, McCarthy MJ, Peters JI. Cystic lung lesions in Sjogren syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. *Ann Diagn Pathol*. 2013 Feb;17(1):113-6.
51. Sharma R, Sirohi D, Sinha R, Menon PS. Reconstruction of a large posterior scalp defect using occipital artery based pedicled island v-y advancement flap: a case report. *J Maxillofac Oral Surg*. 2011 Sep;10(3):262-5.
52. Sharma R, Sirohi D, Sengupta P, Sinha R, Suresh Menon P. Desmoplastic trichilemmoma of the facial region mimicking invasive carcinoma. *J Maxillofac Oral Surg*. 2011 Mar;10(1):71-3.
53. Rohit Sharma, Sirohi D, Sengupta P, Sinha R, Suresh Menon P. Superficial temporal fascia pedicled v-y advancement flap for scalp reconstruction. *J Maxillofac Oral Surg*. 2010 Dec;9(4):410-4.
54. Sirohi D, Sengupta P, Kumar H, Rao PP. Gangliocytic paraganglioma: a rare presentation as intestinal intussusception. *Indian J Pathol Microbiol*. 2010 Oct-Dec;53(4):775-7.
55. Sirohi D, Sengupta P, Kumar H. Methicillin-resistant Staphylococcus pneumonia and underlying asymptomatic sarcoidosis: are they related? A post-mortem case report. *Indian J Pathol Microbiol*. 2010 Apr-Jun;53(2):297-301.
56. Sharma R, Sirohi D. Proximal and distal Facial nerve exploration during superficial parotidectomy. *J Maxillofac Oral Surg*, 2010; 9(2), 150-4.
57. Sirohi D, Sharma R, Sinha R, Suresh Menon P. Salivary gland neoplasms: an analysis of 74 cases. *J Maxillofac Oral Surg*. 2009 Jun;8(2):164-6.
58. Sharma R, Sirohi D, Sinha R, Menon SP. Behcet's Syndrome: a case report. *J Maxillofac Oral Surg*, 2008;7(4), 493-5.
59. Dhot PS, Nair V, Swarup D, Sirohi D, Ganguli P. Cord blood stem cell banking and transplantation. *Indian J Pediatr*, 2003;70(12), 989-92.
60. Dhot PS, Sirohi D, Swamy G. Collection, Separation, Enumeration and Cryopreservation of Umbilical Cord Blood Haematopoietic Stem Cells - An Experimental Study. *Medical Journal Armed Forces India*, 2003;59(4), 298-301.
61. Satyanarayana S, Kalghatgi AT, Malaviya AK, Bhardwaj JR, Muralidhar A, Jawed KZ, Chatterjee T, Trehan A, Sirohi D. Needle necropsy in AIDS. *Indian J Pathol Microbiol*, 2003;46(3), 416-9.

62. Satyanarayana S, Jawed KZ, Sirohi D, Sikdar J. Adamantinoma of Tibia.. Medical Journal Armed Forces India, 2002:58(4), 348-9.

## REVIEW ARTICLES

1. Maughan BL, Sirohi D. Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials. *Curr Treat Options Oncol*. 2023 Jul 6. Online ahead of print.
2. Sirohi D MD, Ohe C, Smith SC, Amin MB. SWI/SNF-deficient neoplasms of the genitourinary tract. *Semin Diagn Pathol*. 2021 May;38(3):212-221.
3. Hahn AW, Sirohi D, Agarwal N. The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. *Eur Urol Focus*. 2020 Jan 15;6(1):11-13.
4. Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. *Res Rep Urol*. 2018 Nov 15;10:205-217.
5. Suryavanshi M, Sanz-Ortega J, Sirohi D, Divatia MK, Ohe C, Zampini C, Luthringer D, Smith SC, Amin MB. S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers. *Adv Anat Pathol*. 2017 May;24(3):151-160.
6. Paner GP, Lopez-Beltran A, Sirohi D, Amin MB. Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. *Adv Anat Pathol*. 2016 Mar;23(2):71-83.
7. Sharma R, Sinha R, Menon PS, Sirohi D. Management protocol for anaphylaxis. *J Oral Maxillofac Surg*. 2010 Apr;68(4):855-62.

## BOOKS AND CHAPTERS

1. Sirohi D. Lipids. In Riddle ND (Ed.), *Laboratory Medicine Pocket (1st Edition)*, 2015. Borm Bruckmeier Publishing, LLC.
2. Sirohi D. Carbohydrates. In Riddle ND (Ed.), *Laboratory Medicine Pocket (1st Edition)*, 2015. Borm Bruckmeier Publishing, LLC.
3. Sirohi D, Jagirdar J. Hemorrhage and Vasculitis. In Cagle PT, Allen TC (Eds.), *Lung and Pleural Pathology (1st Edition)*, 2015. McGraw-Hill Education/Medical.
4. Sirohi D, Paner GP. Verumontanum Mucosal Gland Hyperplasia. In Amin MB, Tickoo SK (Eds.), 2016, *Diagnostic Pathology: Genitourinary (2nd Edition)*. Amirsys Incorporated.
5. Sirohi D, Tickoo SK, Reuter VE. Metastatic Tumors. In Amin MB, Tickoo SK (Eds.), 2016 *Diagnostic Pathology: Genitourinary (2nd Edition)*. Amirsys Incorporated.
6. Sirohi D, Paner GP. Secondary Tumors of Prostate. In Amin MB, Tickoo SK (Eds.), 2016, *Diagnostic Pathology: Genitourinary (2nd Edition)*. Amirsys Incorporated.
7. Sirohi D, Jagirdar J. Malignant Small Cell Tumor of Thoracopulmonary Region/ Primitive Neuroectodermal Tumor/ Askin Tumor, Pleural. In Allen TC, Suster S (Eds.), 2018, *Pathology of the Pleura and Mediastinum (1st Edition)*. Springer International.
8. Pedram A, Agaimay A, Oda Y, Comperat EM, Hartmann A, Colombo P, Montironi R, Rao P, Sirohi D. SMARCB1 deficient Renal Medullary Carcinoma. In: WHO Classification of Tumours Editorial Board. *Urinary and male genital tumours*. Lyon (France): International

Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8).

9. Chevillet J, Srigley JR, Menon S, Mehra R, Bex A, Sirohi D. Renal Cell Carcinoma NOS. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8).
10. Sirohi D, Gupta S, Werneck CI. Juxtaglomerular Cell Tumor. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8).
11. Sirohi D, Amin MB. Glomus Tumors. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8).

## **SIGNIFICANT PUBLICATIONS**

1. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrziewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi D. Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Arch Pathol Lab Med. 2023 Mar 15. Online ahead of print.
2. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzweig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol. 2022 Nov;40(11):493.e1-493.e7.
3. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathin N, Sharma P, Agarwal N, Knudsen B. Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clin Genitourin Cancer. 2022 Jun;20(3):e233-e243.
4. Winter JM, Fresenius HL, Cunningham CN, Wei P, Keys HR, Berg J, Bott A, Yadav T, Ryan J, Sirohi D, Tripp SR, Barta P, Agarwal N, Letai A, Sabatini DM, Wohlever ML, Rutter J. Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. Elife. 2022 Nov 21;11:e82860.
5. Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene. 2022 Oct;41(42):4709-4723.

## **CONFERENCE ABSTRACTS**

1. Marc Barry, Jon Mahlow, Daniel J. Albertson, Yeon Jung Jo, Michael Balatico, Tori Seator, Georges Gebrael, Shruti A. Kumar, Nicolas Sayegh, Nishita Tripathi, Umang Swami, Neeraj Agarwal, Deepika Sirohi. Are Histological Patterns of Prostate Carcinoma Predictive of Homologous Recombination Deficiency Gene Mutations? Accepted for platform presentation at USCAP 2023.

2. Albertson D, Suh IH, Mota S et al. An Independent Prospective Validation of a Deep Learning Algorithm for Prostate Cancer Detection and Gleason Grading. Accepted for platform presentation at USCAP 2023.
3. Albertson D, Mahlow J, Liu T Barry M, Sirohi D. Genotype Phenotype Correlation of Renal Tumor in The Cancer Genome Atlas Database. Accepted for poster presentation at USCAP 2023.
4. Kaushal S, Khandakar H, Mohanty SK, et al. Recognition and Interpretation of Molecularly Defined RCCs Listed in the WHO-2022 Renal Tumor Classification: A Survey of Genitourinary Pathologists. Accepted for poster presentation at USCAP 2023.
5. Wilcock DM, Sirohi D, Lomo LC, et al. Invasive Breast Carcinoma with Micropapillary Features: HER2 status Following 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines and Clinicopathologic Features. Accepted for poster presentation at USCAP 2023.
6. Sirohi D, Jo Y, Knudsen BS. Dysregulation of Genetic Pathways in Histological Growth Patterns of Clear Cell Renal Cell Carcinomas. Accepted for poster presentation at USCAP 2023.
7. Judelson R, Sirohi D, Gebrael G et al. The Morphologic, Clinical and Molecular Spectrum of Succinate Dehydrogenase A-Deficient Renal Cell Carcinoma (SDHA RCC). Accepted for poster presentation at USCAP 2023.
8. Seasor T, Balatico M, Chigarira B et al. Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies. Accepted for poster presentation at ASCO Genitourinary Symposium 2023.
9. U Swami, et al. Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing. *Journal of Clinical Oncology*. 2022;40 (6\_suppl), 133-133
10. D Sirohi, J Coleman, L Furtado, A Grossmann, P Khalili, A Matynia. Unusual Staining Patterns of Mismatch Repair Proteins across Various Tumor Types. *J Mol Diagn*. 2020;22 (5), S64-S65
11. V Sacristan Santos, J Esther, BL Maughan, S Wesolowski, E Lin, A Hahn, D Sirohi, N Rathi, U Swami, R Nussenzeig, N Agarwal. Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs. non-smokers (NS) Presented at ESMO, 2019, Barcelona, Spain. *Annals of Oncology*, 2019, 30:v379
12. Grotepas CB, Abawi J, Coleman JF, Furtado LV, Grossmann G, Matynia AP, Sirohi D, et al. Off-label use of PDL1 (22C3) reveals expression trends: a reference laboratory experience. Poster session presented at USCAP 2018, Vancouver, BC Canada.
13. Sirohi D, van Ziffle J, Grenert JP, Joseph NM, Bastian BC, Yeh I, et al.. Genomic profiling of unclassified renal cell carcinomas. Poster session presented at USCAP 2018, Vancouver, BC, Canada.
14. Paner GP, Sirohi D, Divatia M, Amin MB. Novel and Rare Mesonephric-Type Tumors Arising from the Urologic Tract. Poster session presented at United States & Canadian Academy of Pathology (USCAP) Meeting, Seattle, WA, 2016.
15. Gulavita P, Zhou M, Amin MB, Sirohi D, Garcia E, Dal Cin P, et al. Morphologic and Molecular Evaluation of Thyroid-Like Follicular Carcinoma of the Kidney. Poster session



- presented at United States & Canadian Academy of Pathology (USCAP) Meeting, Seattle, WA, 2016.
16. Sadimin E, Parikh M, Luthringer D, Sirohi D, Amin MB, Epstein J. Clinicopathological Characteristics of Patients with Fungal Prostatitis. Poster session presented at United States & Canadian Academy of Pathology (USCAP) Meeting, Seattle, WA.
  17. Sirohi D, Smith SC, Ohe C, de Peralta-Venturina M, Luthringer DJ, Tomlins SA, et al. Prostate Cancer with Overlapping Features of Small Cell Carcinoma and Acinar Adenocarcinoma: A Critical Appraisal of Morphology and Correlation with Novel and Traditional Immunohistochemical Markers. Poster session presented at United States & Canadian Academy of Pathology (USCAP) Meeting, Seattle, WA, 2016.
  18. Sirohi D, Fukuoka J, Hori T, Jagirdar J. Comparison of high molecular weight cytokeratins 5/14 and 5/6; p40 and Desmoglein3+cytokeratin5 In Squamous Cell Carcinomas. Poster session presented at College of American Pathologists (CAP) Annual Meeting, Orlando, FL, 2013.
  19. Sirohi D, Nicolas MM, Prihoda TJ, Werner SL. Renal Cell Carcinoma: Do Diabetics Differ from Non-Diabetics? Poster session presented at United States & Canadian Academy of Pathology (USCAP) Meeting, Baltimore, MD, 2013.
  20. Sirohi D, Fukuoka J, Hori T, Cagle PT, Jagirdar J. Fibulin-3 expression In mesothelioma and carcinomas from different sites. Poster session presented at College of American Pathologists (CAP) Annual Meeting, Orlando, FL, 2013.
  21. Sirohi D, Fukuoka J, Hori T, Jagirdar J. A novel antibody profile (CK5/14 Cocktail & p40) defines 3 major subsets of Urothelial Carcinoma of the Urinary Bladder. Poster session presented at College of American Pathologists (CAP) Annual Meeting, Orlando, FL, 2013.
  22. Sirohi D, Kinney MC, Higgins RA. IgG4 related sclerosing disease: a review of 3 cases. Poster session presented at 91st Annual meeting of the Texas Society of Pathologists, Dallas, TX, 2012.
  23. Sirohi D, Datta S, Rai R, Rode S. Recurrent Herpes Gestationis: a case report. Poster session presented at 50th Annual Conference of the Indian Association of Pathologists and Microbiologists (IAPM), Mumbai, India, 2001.
  24. Sirohi D, Satyanaryana S, Sanyal SK. Cutaneous sarcoidosis. Poster session presented at XV Annual Conference of the Indian Association of Pathologists and Microbiologists (IAPM), Delhi Chapter, New Delhi, India., 2000.